<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2019.10568</article-id>
<article-id pub-id-type="publisher-id">mmr-20-04-3113</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Downregulation of miR-16 protects H9c2(2-1) cells against hypoxia/reoxygenation damage by targeting CIAPIN1 and regulating the NF-&#x03BA;B pathway</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Hai-Jin</given-names></name>
<xref rid="af1-mmr-20-04-3113" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yi-Na</given-names></name>
<xref rid="af1-mmr-20-04-3113" ref-type="aff"/>
<xref rid="c1-mmr-20-04-3113" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Teng</surname><given-names>Zong-Yan</given-names></name>
<xref rid="af1-mmr-20-04-3113" ref-type="aff"/></contrib>
</contrib-group>
<aff id="af1-mmr-20-04-3113">Department of Geriatrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-20-04-3113"><italic>Correspondence to</italic>: Dr Yi-Na Zhang, Department of Geriatrics, The Second Affiliated Hospital of Harbin Medical University, 246 Xue Fu Road, NanGang, Harbin, Heilongjiang 150001, P.R. China, E-mail: <email>erkuang110@tom.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>10</month><year>2019</year></pub-date>
<pub-date pub-type="epub"><day>07</day><month>08</month><year>2019</year></pub-date>
<volume>20</volume>
<issue>4</issue>
<fpage>3113</fpage>
<lpage>3122</lpage>
<history>
<date date-type="received"><day>04</day><month>12</month><year>2018</year></date>
<date date-type="accepted"><day>08</day><month>07</month><year>2019</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Zhang et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>The aim of the present study was to determine the function of microRNA-16 (miR-16) in myocardial hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury and the possible mechanism underlying its involvement. An H/R model was constructed using H9c2(2-1) cells <italic>in vitro</italic>. The results of reverse transcription-quantitative PCR demonstrated that the expression levels of miR-16 were significantly upregulated in H9c2(2-1) cells in the H/R group compared with the sham group (1.53&#x00B1;0.09 vs. 1.0&#x00B1;0.08; P=0.0019). Cell Counting Kit-8 assays revealed that the relative proliferative ability of H9c2(2-1) cells was significantly decreased in the H/R &#x002B; negative control (NC) group compared with the sham group (0.53&#x00B1;0.05 vs. 1.0&#x00B1;0.08; P=0.00005). Upregulation of miR-16 using miR-16 mimics further decreased the proliferative ability of cells (0.31&#x00B1;0.03 vs. 0.53&#x00B1;0.05; P=0.0097), whereas downregulation of miR-16 using an miR-16 inhibitor increased the proliferative ability of cells compared with the H/R&#x002B;NC group (0.89&#x00B1;0.08 vs. 0.53&#x00B1;0.05; P=0.000385). Flow cytometric analysis found that the apoptotic rate of H9c2(2-1) cells was increased significantly following H/R compared with the sham group (25.86&#x00B1;2.62&#x0025; vs. 9.29&#x00B1;0.82&#x0025;, P=0.000014). Upregulation of miR-16 further increased the apoptotic rate (38.62&#x00B1;2.04&#x0025; vs. 25.86&#x00B1;2.62&#x0025;; P=0.000099), whereas downregulation of miR-16 decreased the apoptotic rate compared with the H/R&#x002B;NC group (15.14&#x00B1;0.92&#x0025; vs. 25.86&#x00B1;2.62&#x0025;; P=0.000343). miR-16 directly bound to the 3&#x2032;-untranslated region of cytokine-induced apoptosis inhibitor 1 (CIAPIN1) and negatively modulated CIAPIN1 expression. Overexpression of CIAPIN1 reversed the changes in the expression of apoptosis-associated proteins caused by H/R. Western blot analysis revealed that the levels of phospho-(p-)nuclear factor-&#x03BA;B (NF-&#x03BA;B) and p-NF-&#x03BA;B inhibitor &#x03B1; (I&#x03BA;B&#x03B1;) were upregulated following H/R (1.82&#x00B1;0.11 vs. 1.0&#x00B1;0.08; P=0.000152; and 1.77&#x00B1;0.07 vs. 1.0&#x00B1;0.00; P=0.000024, respectively), and these changes were further enhanced when miR-16 expression levels were increased (3.10&#x00B1;0.14 vs. 1.82&#x00B1;0.11; P=0.000006; and 2.19&#x00B1;0.10 vs. 1.77&#x00B1;0.07; P=0.0017, respectively). Downregulation of miR-16 exhibited the opposite effect on p-NF-&#x03BA;B and p-I&#x03BA;B&#x03B1; expression levels. The present study illustrates that downregulation of miR-16 may protect against H/R-induced injury partially by targeting CIAPIN1 and the NF-&#x03BA;B signaling pathway.</p>
</abstract>
<kwd-group>
<kwd>microRNA-16 mimics</kwd>
<kwd>microRNA-16 inhibitor</kwd>
<kwd>hypoxia/reoxygenation</kwd>
<kwd>cytokine induced apoptosis inhibitor 1</kwd>
<kwd>nuclear factor-&#x03BA;B pathway</kwd>
</kwd-group></article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hypoxia may result in an insufficient supply of blood and nutrients to the heart, resulting in cardiomyocytes undergoing apoptosis, which may potentially injure the cardiac tissue (<xref rid="b1-mmr-20-04-3113" ref-type="bibr">1</xref>). Myocardial infarction, a normal ischemic heart disease, is one of the primary causes of disability and the leading cause of mortality worldwide (<xref rid="b2-mmr-20-04-3113" ref-type="bibr">2</xref>). At present, the most effective therapy for treating patients following a myocardial infarction is reperfusion, a process of rapidly restoring the blood flow through the occluded coronary artery (<xref rid="b3-mmr-20-04-3113" ref-type="bibr">3</xref>&#x2013;<xref rid="b5-mmr-20-04-3113" ref-type="bibr">5</xref>). Reperfusion will result in myocardial ischemia/reperfusion (MI/R) injury, which will result in additional death of cardiomyocytes and will enlarge the size of the infarction (<xref rid="b4-mmr-20-04-3113" ref-type="bibr">4</xref>,<xref rid="b6-mmr-20-04-3113" ref-type="bibr">6</xref>,<xref rid="b7-mmr-20-04-3113" ref-type="bibr">7</xref>). A deeper understanding of the molecular mechanism underlying MI/R injury may improve treatments and reduce MI/R-associated damage.</p>
<p>There is increasing evidence illustrating the roles of micro-RNAs (miRNAs) in the modulation of numerous biological processes in diseases, including MI/R injury (<xref rid="b8-mmr-20-04-3113" ref-type="bibr">8</xref>&#x2013;<xref rid="b10-mmr-20-04-3113" ref-type="bibr">10</xref>). miRNAs, which are members of the non-coding small RNA family, are involved in gene silencing by binding to the 3&#x2032;-untranslated region (3&#x2032;-UTR) of its target genes (<xref rid="b11-mmr-20-04-3113" ref-type="bibr">11</xref>,<xref rid="b12-mmr-20-04-3113" ref-type="bibr">12</xref>). Several differentially expressed miRNAs, including miR-21 (<xref rid="b13-mmr-20-04-3113" ref-type="bibr">13</xref>), miR-24 (<xref rid="b14-mmr-20-04-3113" ref-type="bibr">14</xref>) and miR-29 (<xref rid="b15-mmr-20-04-3113" ref-type="bibr">15</xref>), have been demonstrated to be involved in I/R-induced injury. miR-16 was identified as an anti-apoptotic factor in glioblastoma multiforme (<xref rid="b11-mmr-20-04-3113" ref-type="bibr">11</xref>).</p>
<p>In the present study, the mRNA expression levels of miR-16 were significantly increased in H9c2(2-1) cardiac myoblast cells following simulation of H/R, suggesting an important role of miR-16 in H/R-injury response. In addition, the potential target genes of miR-16 were examined. It was demonstrated that miR-16 may reduce the damage of cardiac myoblast cells caused by H/R, partially by downregulating the expression of cytokine-induced apoptosis inhibitor 1 (CIAPIN1). To the best of our knowledge, the present study is the first to study the specific role of miR-16 in H/R injury.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture and construction of an H/R model</title>
<p>The H9c2(2-1) cardiac myoblasts cell line (henceforth referred to as H9c2) was purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco&#x0027;s modified Eagle&#x0027;s medium (DMEM) supplemented with 10&#x0025; FBS, 100 U/ml penicillin and 100 &#x00B5;g/ml streptomycin at 37&#x00B0;C with 95&#x0025; atmosphere and 5&#x0025; CO<sub>2</sub>. To construct the H/R model, H9c2 cells were transferred into DMEM without FBS before being subjected to hypoxia. The cells were incubated at 37&#x00B0;C for 6 h in an anaerobic chamber containing 95&#x0025; N<sub>2</sub> and 5&#x0025; CO<sub>2</sub>. Subsequently, the cells were moved to a normoxic incubator (5&#x0025; CO<sub>2</sub> and 95&#x0025; atmosphere) with DMEM and incubated for 24 h for re-oxygenation. The same treatment was performed in the sham group without the hypoxic stimulus.</p>
</sec>
<sec>
<title>Transfection of miR-16 mimics/inhibitor</title>
<p>To investigate the role of miR-16, the miR-16 mimics, miR-16 inhibitor and their corresponding negative controls (NC) were all synthesized by GenePharma Co., Ltd. (Shanghai, China). The sequences of miR-16 mimics and the negative control (NC) were: 5&#x2032;-UAGCAGCACGUAAAUAUUGGUG-3&#x2032; and 5&#x2032;-UACACCGAUCGAGUCAGGUTT-3&#x2032;, respectively. The sequences of the miR-16 inhibitor and its NC were 5&#x2032;-CACCAAUAUUUACGUGCUGCUA-3&#x2032; and 5&#x2032;-UCGAGACACGUACGCAGAATT-3&#x2032;, respectively. A pcDNA3.1-CIAPIN1 plasmid was constructed by GenePharma Co., Ltd. to overexpress CIAPIN1, and an empty pcDNA3.1 vector (GenePharma Co., Ltd.) was used as the NC. H9c2 cells were seeded into 24-well plates and grown to ~60&#x0025; confluence. The miR-16 mimics, miR-16 inhibitor, pcDNA3.1-CIAPIN1 and their corresponding NCs were transfected into the cells using Lipofectamine<sup>&#x00AE;</sup> 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham MA, USA) according to the manufacturer&#x0027;s protocol. The final concentration of miR-16 mimics and its NC was 50 nM, and the final concentration for miR-16 inhibitor and NC was 100 nM. The expression level of miR-16 was detected by reverse transcription-quantitative (RT-q)PCR 24 h after transfection.</p>
</sec>
<sec>
<title>Dual-luciferase reporter gene assay</title>
<p>The potential targets of miR-16 were predicted using the TargetScan website (<uri xlink:href="http://www.targetscan.org/vert_72/">http://www.targetscan.org/vert_72/</uri>). CIAPIN1 was predicted as a target of miR-16. In order to confirm that miR-16 directly bound to CIAPIN1, a dual-luciferase reporter gene assay was performed. The 3&#x2032;-UTR of CIAPIN1 containing the miR-16-binding sites (CIAPIN1-WT) and 3&#x2032;-UTR of CIAPIN1 containing the mutant miR-16-binding sites (CIAPIN1-Mut) were synthesized. The CIAPIN1-WT and CIAPIN1-Mut were cloned into pmiR-RB-REPORT&#x2122; plasmid (Guangzhou RiboBio Co., Ltd.). Each recombinant vector, pmiR-CIAPIN1-WT or pmiR-CIAPIN1-Mut, along with miR-16 mimics or miR-16 mimics NC, were co-transfected into the H9c2 cells using Lipofectamine&#x2122; 3000 reagent, according to the manufacturer&#x0027;s protocol. After 48 h of transfection, the total protein was extracted, and the luciferase activity was detected using a Dual-Luciferase Reporter assay kit (Promega Corporation, Madison, WI, USA), according to the manufacturer&#x0027;s protocol. The activity of Renilla luciferase was used for normalization.</p>
</sec>
<sec>
<title>Cell Counting Kit-8 (CCK-8) assay</title>
<p>A CCK-8 assay (Beyotime Institute of Biotechnology, Haimen, China) was used to examine the proliferative ability of H9c2 cells after 24 h transfection. Single cell suspensions were prepared and seeded into 96-well plates with 1&#x00D7;10<sup>3</sup> cells/well. The plates were incubated at 37&#x00B0;C with 5&#x0025; CO<sub>2</sub>. After a 24 h incubation, 10 &#x00B5;l CCK-8 reagent was added to each well and incubated at 37&#x00B0;C for 1.5 h. Subsequently, the absorbance was detected at 450 nm using an ELx800 microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).</p>
</sec>
<sec>
<title>RT-qPCR</title>
<p>Cells were harvested 24 h after transfection and the total RNA was extracted using TRIzol<sup>&#x00AE;</sup> (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer&#x0027;s protocol. For mRNA expression analysis, the isolated RNA was reverse-transcribed to cDNA using a PrimeScript&#x2122; RT Reagent kit (Takara Bio, Inc.). The RT procedure was: 37&#x00B0;C for 15 min and then 85&#x00B0;C for 15 sec. qPCR was performed using SYBR Premix Ex Taq II (Takara Bio, Inc.) on a 7500 Real Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). To determine the level of miR-16, Mir-X&#x2122; miRNA First Strand Synthesis kit (Takara Bio, Inc.) was used to reverse-transcribe the RNA to cDNA according to the supplier&#x0027;s instruction. qPCR was then performed using SYBR PrimeScript&#x2122; miRNA RT-PCR kit (Takara Bio, Inc.). The PCR steps including 95&#x00B0;C for 5 min, followed by 40 cycles of 5 sec at 95&#x00B0;C, 34 sec at 60&#x00B0;C, and then 72&#x00B0;C for 30 min. The expression of GAPDH and U6 small nuclear RNA were used as internal references for mRNA and miRNA accordingly. The relative expression of CIAPIN1 and miR-16 was calculated using the 2<sup>&#x2212;&#x0394;&#x0394;Cq</sup> method (<xref rid="b16-mmr-20-04-3113" ref-type="bibr">16</xref>). All the primers used for qPCR are presented in <xref rid="tI-mmr-20-04-3113" ref-type="table">Table I</xref>. The U6 small nuclear RNA primers and uni-miR qPCR primer were included with the SYBR PrimeScript&#x2122; miRNA RT-PCR kit.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Total cellular proteins were extracted from H9c2 cells using the RIPA lysate with protease inhibitors (CWBIO, Beijing, China. <uri xlink:href="http://www.cwbiotech.com/">http://www.cwbiotech.com/</uri>) after 48 h transfection. Proteins (20 &#x00B5;g each well) were then separated by SDS-PAGE with a 10&#x0025; gel. Subsequently, the proteins from the gel were transferred to a PVDF membrane (EMD Millipore, Billerica, MA, USA). Then the membranes were blocked by 5&#x0025; skimmed milk for 1 h at room temperature. Then the membranes were incubated with primary antibodies for 12 h, and then the secondary antibody for 1 h at 4&#x00B0;C. The signals were visualized using enhanced chemiluminescent reagent, and the expression of &#x03B2;-actin was used for normalization. The following primary antibodies were used, Bcl-2 (Abcam, Cambridge, UK; cat. no. ab196495; 1:1,000), Bax (Abcam; cat. no. ab53154; 1:1,000), cleaved caspase-3 (Abcam; cat. no. ab49822; 1:1,000), CIAPIN1 (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. PA5-59903; 1:1,000), NF-&#x03BA;B (Abcam; cat. no. ab16502; 1:1,000), p-NF-&#x03BA;B (CST Biological Reagents Co., Ltd., Shanghai, China; cat. no. 3039, 1:1,000), I&#x03BA;B&#x03B1; (Abcam; cat. no. ab7217; 1:1,000), p-I&#x03BA;B&#x03B1; (CST, cat. no. 2859; 1:1,000) and &#x03B2;-actin (CST Biological Reagents Co., Ltd., cat. no. 4970; 1:1,000). The anti-rabbit immunoglobulin G, horseradish peroxidase-linked antibody of CST Biological Reagents Co., Ltd. (cat. no. 7074; 1:2,000) was used as the secondary antibody. Quantity One 4.6.2 software (Bio-Rad Laboratories, Inc.) was used for densitometry analysis.</p>
</sec>
<sec>
<title>Cell apoptosis analysis</title>
<p>Flow cytometry was used to evaluate the apoptosis of H9c2 cells. Cells were harvested by centrifugation (300 &#x00D7; g, 5 min, 4&#x00B0;C) and washed using pre-cooled PBS. Cells were resuspended in binding buffer(Sigma-Aldrich; Merck KGaA) at a final concentration of 1.5&#x00D7;10<sup>6</sup> cells/ml. Double staining was performed with an Annexin V-fluorescein isothiocyanate (FITC)/propidium staining (PI) kit, according to the manufacturer&#x0027;s protocol (Sigma-Aldrich; Merck KGaA; Darmstadt, Germany). Staining was measured using flow cytometry (BD Biosciences) and analyzed with FlowJo software 7.2 (FlowJo LLC).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>All the results are presented as the mean &#x00B1; standard deviation. Comparisons between two groups were analyzed using a Student&#x0027;s t-test. Comparisons between multiple groups were analyzed using a one-way ANOVA, followed by a post hoc Tukey&#x0027;s or Dunnett&#x0027;s test. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>miR-16 expression is upregulated in H9c2 cells following hypoxia</title>
<p>The mRNA expression levels of miR-16 in H9c2 cells increased 1.53-fold following hypoxic treatment compared with the H9c2 cells in the sham group (P=0.0019; <xref rid="f1-mmr-20-04-3113" ref-type="fig">Fig. 1A</xref>). To determine the possible biological functions of miR-16, miR-16 mimics and miR-16 inhibitor were used to upregulate or downregulate the expression of miR-16 in H9c2 cells, respectively. The mRNA expression levels of miR-16 were significantly increased in H9c2 cells transfected with miR-16 mimics (1.59&#x00B1;0.10 vs. 0.98&#x00B1;0.08; P=0.000026) and significantly decreased in H9c2 cells transfected with miR-16 inhibitor (0.56&#x00B1;0.05 vs. 1.05&#x00B1;0.09; P=0.000299; <xref rid="f1-mmr-20-04-3113" ref-type="fig">Fig. 1B</xref>) compared with the respective NC. When H/R was simulated in the H9c2 cells, the expression of miR-16 was also increased in cells transfected with miR-16 mimics (1.98&#x00B1;0.15 vs. 1.53&#x00B1;0.01; P=0.002205) and decreased by miR-16 inhibitors (1.16&#x00B1;0.09 vs. 1.52&#x00B1;0.01; P=0.006857 <xref rid="f1-mmr-20-04-3113" ref-type="fig">Fig. 1C</xref>) compared with the respective NC.</p>
</sec>
<sec>
<title>miR-16 regulates the proliferation and apoptosis of H9c2 cells following hypoxia</title>
<p>A CCK-8 assay and flow cytometry were performed to examine the role exerted by miR-16 on the proliferation and apoptosis of H9c2 cells following hypoxia. The viability of H9c2 cells was significantly reduced in the H/R&#x002B;NC group compared with the sham group (0.53&#x00B1;0.05 vs. 1.00&#x00B1;0.08; P=0.000003; <xref rid="f2-mmr-20-04-3113" ref-type="fig">Fig. 2</xref>). Upregulation of miR-16 using miR-16 mimics (H/R&#x002B;miR-16 mimics group) further decreased proliferation of H9c2 cells compared with the H/R&#x002B;NC group (0.31&#x00B1;0.03 vs. 0.53&#x00B1;0.05; P=0.0097; <xref rid="f2-mmr-20-04-3113" ref-type="fig">Fig. 2</xref>). Downregulation of miR-16 using the miR-16 inhibitor significantly increased the proliferation of H9c2 cells compared with the H/R&#x002B;NC group (0.89&#x00B1;0.08 vs. 0.53&#x00B1;0.05; P=0.000385; <xref rid="f2-mmr-20-04-3113" ref-type="fig">Fig. 2</xref>).</p>
<p>Furthermore, flow cytometric analysis demonstrated that that the apoptotic percentage was significantly increased in the H/R&#x002B;NC group compared with the sham group (25.86&#x00B1;2.62&#x0025; vs. 9.29&#x00B1;0.82&#x0025;; P=0.000014; <xref rid="f3-mmr-20-04-3113" ref-type="fig">Fig. 3</xref>). Compared with the H/R&#x002B;NC group, the apoptotic percentage was increased in the H/R&#x002B;miR-16 mimics group (38.62&#x00B1;2.04&#x0025; vs. 25.86&#x00B1;2.62&#x0025;; P=0.000099; <xref rid="f3-mmr-20-04-3113" ref-type="fig">Fig. 3</xref>), whereas in the H/R&#x002B;miR-16 inhibitor group the apoptotic rate was significantly decreased (15.14&#x00B1;0.92&#x0025; vs. 25.86&#x00B1;2.62&#x0025;; P=0.000343; <xref rid="f3-mmr-20-04-3113" ref-type="fig">Fig. 3</xref>) compared with the H/R&#x002B;NC group. The expression levels of apoptosis-associated proteins were determined by western blotting (<xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4A</xref>). The results demonstrated that the expression of Bcl-2 (0.49&#x00B1;0.05 vs. 1.00&#x00B1;0.03; P=0.000004; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4B</xref>) was decreased; whereas the levels of Bax (1.60&#x00B1;0.06 vs. 1.00&#x00B1;0.05; P=0.000005; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4C</xref>) and cleaved caspase-3 (1.54&#x00B1;0.07 vs. 0.96&#x00B1;0.03; P=0.00001; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4D</xref>) were increased in the H/R&#x002B;NC group compared with the sham group. Compared with the H/R&#x002B;NC group, the expression of Bcl-2 (0.27&#x00B1;0.07 vs. 0.49&#x00B1;0.05; P=0.00193; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4B</xref>) was decreased, whereas the levels of Bax (2.20&#x00B1;0.04 vs. 1.60&#x00B1;0.06; P=0.000005; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4C</xref>) and cleaved caspase-3 (2.17&#x00B1;0.09 vs. 1.54&#x00B1;0.07; P=0.000012; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4D</xref>) were increased in the H/R&#x002B;miR-16 mimics group. In the H/R&#x002B;miR-16 inhibitor group, the expression of Bcl-2 (0.73&#x00B1;0.02 vs. 0.49&#x00B1;0.05; P=0.000983; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4B</xref>) was increased, whilst the levels of Bax (1.26&#x00B1;0.07 vs. 1.60&#x00B1;0.06; P=0.000394; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4C</xref>) and cleaved caspase-3 (1.27&#x00B1;0.08 vs. 1.54&#x00B1;0.07; P=0.001939; <xref rid="f4-mmr-20-04-3113" ref-type="fig">Fig. 4D</xref>) were declined compared with the H/R&#x002B;NC group.</p>
</sec>
<sec>
<title>miR-16 negatively regulates the expression of CIAPIN1</title>
<p>To further examine how miR-16 affected cell proliferation and apoptosis in H/R injury, the target was predicted using TargetScan. CIAPIN1 was one of the targets of miR-16, and the predicted binding sites are shown in <xref rid="f5-mmr-20-04-3113" ref-type="fig">Fig. 5A</xref>. The results of the luciferase reporter assay revealed that the relative luciferase activity of CIAPIN1-WT was dramatically decreased in the H/R&#x002B;miR-16 mimics group compared with the H/R&#x002B;miR-16 mimics NC group (P&#x003C;0.01; <xref rid="f5-mmr-20-04-3113" ref-type="fig">Fig. 5B</xref>). However, upregulation of miR-16 did not significantly influence the luciferase activity of CIAPIN1-Mut (P&#x003E;0.05; <xref rid="f5-mmr-20-04-3113" ref-type="fig">Fig. 5B</xref>). Therefore, the effect of miR-16 on CIAPIN1 expression was determined by qPCR and western blotting. The mRNA and protein expression levels of CIAPIN1 were decreased significantly in the H/R&#x002B;NC group compared with the sham group (both P&#x003C;0.01; <xref rid="f6-mmr-20-04-3113" ref-type="fig">Fig. 6</xref>). Upregulation of miR-16 using miR-16 mimics further decreased CIAPIN1 expression at both the mRNA (<xref rid="f6-mmr-20-04-3113" ref-type="fig">Fig. 6A</xref>) and protein expression levels (<xref rid="f6-mmr-20-04-3113" ref-type="fig">Fig. 6</xref>) in comparison with H/R&#x002B;NC group (both P&#x003C;0.01). CIAPIN1 expression was enhanced in the H/R&#x002B;miR-16 inhibitor group compared with the H/R&#x002B;NC group (P=0.000858).</p>
</sec>
<sec>
<title>Overexpression of CIAPIN1 reverses the changes of expression of apoptosis-associated proteins caused by H/R</title>
<p>CIAPIN1 was overexpressed in H9c2 cells to determine its effect on apoptosis. As shown in <xref rid="f7-mmr-20-04-3113" ref-type="fig">Fig. 7A-C</xref>, the mRNA and protein expression levels of CIAPIN1 were significantly increased in H9c2 cells in the CIAPIN1-overexpression group compared with the control (P&#x003C;0.01). The effect of CIAPIN1 overexpression on the expression of Bcl-2 and Bax in H9c2 cells following H/R was determined by western blotting. The results showed that the expression levels of Bcl-2 were significantly increased, whereas the expression of Bax was significantly decreased in H/R-damaged H9c2 cells transfected with CIAPIN1-OE compared with the H/R&#x002B; CIAPIN1-OE group (<xref rid="f7-mmr-20-04-3113" ref-type="fig">Fig. 7D and E</xref>; P=0.035; P=0.032). These data suggested that overexpression of CIAPIN1 reversed the changes in expression of apoptosis-associated proteins caused by H/R, suggesting that overexpression of CIAPIN1 reduced apoptosis induced by H/R injury.</p>
</sec>
<sec>
<title>The NF-&#x03BA;B pathway may be involved in miR-16-mediated protective effects following myocardial ischemia</title>
<p>Western blotting was performed to determine the influence of miR-16 expression on the NF-&#x03BA;B signaling pathway. The results demonstrated that the expression levels of NF-&#x03BA;B and inhibitor of NF-&#x03BA;B alpha (I&#x03BA;B&#x03B1;) remained relatively unchanged despite the change in miR-16 expression. However, the expression levels of p-NF-&#x03BA;B and p-I&#x03BA;B&#x03B1; were significantly upregulated in H9c2 cells following H/R (<xref rid="f8-mmr-20-04-3113" ref-type="fig">Fig. 8</xref>; 1.82&#x00B1;0.11 vs. 1.00&#x00B1;0.08, P=0.000152; and 1.77&#x00B1;0.07 vs. 1.00&#x00B1;0.00, P=0.000024, respectively). Upregulation of miR-16 using miR-16 mimics further increased the levels of p-NF-&#x03BA;B and p-I&#x03BA;B&#x03B1; compared with the H/R&#x002B;NC group (<xref rid="f8-mmr-20-04-3113" ref-type="fig">Fig. 8</xref>; 3.10&#x00B1;0.14 vs. 1.82&#x00B1;0.11, P=0.000006; and 2.19&#x00B1;0.10 vs. 1.77&#x00B1;0.07, P=0.0017, respectively). In contrast, the expression levels of p-NF-&#x03BA;B and p-I&#x03BA;B&#x03B1; were decreased in the cells transfected with the miR-16 inhibitor group compared with the H/R&#x002B;NC group (<xref rid="f8-mmr-20-04-3113" ref-type="fig">Fig. 8</xref>; 1.26&#x00B1;0.13 vs. 1.82&#x00B1;0.11, P=0.002; and 1.45&#x00B1;0.12 vs. 1.77&#x00B1;0.06, P=0.009).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>miRNAs have been demonstrated to serve important roles in the regulation of MI/R injury (<xref rid="b17-mmr-20-04-3113" ref-type="bibr">17</xref>). In the present study, miR-16 expression was enhanced in H9c2 cells following simulation of H/R. Upregulation of miR-16 expression enhanced the inhibitory effects on H9c2 cell proliferation caused by H/R. Downregulation of miR-16 expression reduced the suppressive effects of H/R on cell proliferation as well as cell apoptosis. These observations suggested that downregulation of miR-16 may mitigate H/R-induced injury. Higher expression levels of miR-16 have been observed in the urine of patients with acute kidney injury (AKI). The researchers identified that miR-16 was transactivated by C/EBP-&#x03B2;, which aggravated the I/R-induced AKI (<xref rid="b18-mmr-20-04-3113" ref-type="bibr">18</xref>), consistent with the results of the present study.</p>
<p>To date, the majority of the research surrounding miR-16 has been focused on its role in cancer, and there are conflicting reports on its function based on the type of cancer studied (<xref rid="b19-mmr-20-04-3113" ref-type="bibr">19</xref>&#x2013;<xref rid="b22-mmr-20-04-3113" ref-type="bibr">22</xref>), suggesting that it may target distinct genes in different organs resulting in varied effects (<xref rid="b18-mmr-20-04-3113" ref-type="bibr">18</xref>). Among the numerous targets of miR-16, a focus was placed on the CIAPIN1 gene in the recent study. CIAPIN1 is a novel apoptosis inhibitor with no association with apoptosis regulators in the Bcl-2 and caspase families (<xref rid="b23-mmr-20-04-3113" ref-type="bibr">23</xref>). Furthermore, it has been identified as an important downstream effector of the Ras signaling pathway (<xref rid="b24-mmr-20-04-3113" ref-type="bibr">24</xref>). At present, numerous studies have shown that CIAPIN1 exhibits different functions based on the physiological and pathological conditions (<xref rid="b25-mmr-20-04-3113" ref-type="bibr">25</xref>&#x2013;<xref rid="b27-mmr-20-04-3113" ref-type="bibr">27</xref>). In large B-cell lymphoma and ovarian cancer, CIAPIN1 exhibited anti-apoptotic effects and facilitated proliferation (<xref rid="b26-mmr-20-04-3113" ref-type="bibr">26</xref>). However, in esophageal cancer and renal cell carcinoma, CIAPIN1 exhibited an inhibitory effect on tumor cell viability (<xref rid="b27-mmr-20-04-3113" ref-type="bibr">27</xref>). In hypoxia-induced cardiomyocytes, CIAPIN1 has been illustrated to be a target of miR-182-5p, and the expression of CIAPIN1 was dramatically decreased following hypoxia (<xref rid="b1-mmr-20-04-3113" ref-type="bibr">1</xref>). Furthermore, CIAPIN1 overexpression reduced the H/R-induced damage in H9c2 myocytes (<xref rid="b28-mmr-20-04-3113" ref-type="bibr">28</xref>). In the present study, CIAPIN1 was predicted as one of the targets of miR-16. Using a luciferase reporter assay, it was confirmed that miR-16 directly regulated the expression of CIAPIN1 by binding to its 3&#x2032;-UTR. Expression of CIAPIN1 was downregulated in H9c2 cells following H/R. Increasing expression of miR-16 using miR-16 mimics further decreased both the mRNA and protein expression levels of CIAPIN1 following H/R compared with the H/R&#x002B;NC group. In contrast, downregulation of miR-16 using an inhibitor resulted in a significant increase in the expression of CIAPIN1 compared with the H/R&#x002B;NC group. These observations illustrate that CIAPIN1 may be negatively regulated by miR-16.</p>
<p>MI/R is associated with a serious inflammatory response. NF-&#x03BA;B transcription factors take part in a number of physiological processes, including inflammation, immunity and tumorigenicity (<xref rid="b29-mmr-20-04-3113" ref-type="bibr">29</xref>). In the non-activated state, NF-&#x03BA;B exists as a heterotrimer composed of p50, p65 and I&#x03BA;B subunits in the cytoplasm. Upon activation, I&#x03BA;B&#x03B1; is phosphorylated, and subsequently degraded, allowing p65 to translocate to the nucleus and bind to the DNA, leading to gene transcription (<xref rid="b29-mmr-20-04-3113" ref-type="bibr">29</xref>). Numerous studies have suggested the involvement of the NF-&#x03BA;B signaling pathway in the pathogenesis of MI/R (<xref rid="b30-mmr-20-04-3113" ref-type="bibr">30</xref>&#x2013;<xref rid="b32-mmr-20-04-3113" ref-type="bibr">32</xref>). In myocardial tissues of MI/R mice, the expression of I&#x03BA;B&#x03B1; was significantly increased, and it was reported that downregulation of miR-27a protected mice against MI/R injury, partially by modulating the NF-&#x03BA;B signaling pathway (<xref rid="b31-mmr-20-04-3113" ref-type="bibr">31</xref>). In rats, myocardial NF-&#x03BA;B expression was significantly increased following MI/R, highlighting its potential role in MI/R (<xref rid="b30-mmr-20-04-3113" ref-type="bibr">30</xref>). In the present study, the relative expression levels of p-NF-&#x03BA;B and p-I&#x03BA;B&#x03B1; were upregulated in H9c2 cells following H/R. Upregulation or downregulation of miR-16 significantly increased or decreased the expression levels of p-NF-&#x03BA;B and p-I&#x03BA;B&#x03B1; levels. Therefore, it was hypothesized that downregulation of miR-16 may reduce H/R injury, at least partially through suppression of the NF-&#x03BA;B signaling pathway, which results in decreased levels of inflammatory cytokines, and subsequently reduced apoptosis. In ulcerative colitis, miR-16 was demonstrated to participate in regulating the NF-&#x03BA;B signaling pathway by modulating the expression of the adenosine A2a receptor (<xref rid="b33-mmr-20-04-3113" ref-type="bibr">33</xref>). Upregulation of miR-16 increased activation of the NF-&#x03BA;B signaling pathway in ulcerative colitis (<xref rid="b33-mmr-20-04-3113" ref-type="bibr">33</xref>), and this result was consistent with the results of the present study. In the bladder cancer cell line, T24, upregulation of miR-16 resulted in deactivation of the NF-&#x03BA;B signaling pathway (<xref rid="b34-mmr-20-04-3113" ref-type="bibr">34</xref>). In addition, miR-16 was reported to decrease glioma malignancy by downregulating NF-&#x03BA;B (<xref rid="b35-mmr-20-04-3113" ref-type="bibr">35</xref>). These seemingly opposite results may result from differences in the tissues used and the diseases studied. Reports regarding the association between CIAPIN1 and the NF-&#x03BA;B signaling pathway are rare. In K562 chronic myeloid leukemia cells, depletion of CIAPIN1 led to relatively lower levels of p-IKK&#x03B1;/&#x03B2; and p-I&#x03BA;B&#x03B1; compared with CIAPIN1 scramble-transfected K562 cells (<xref rid="b24-mmr-20-04-3113" ref-type="bibr">24</xref>). However, in the present study, the expression levels of CIAPIN1 were relatively higher in the miR-16 inhibitor group, whereas the expression levels of p-I&#x03BA;B&#x03B1; and p-NF-&#x03BA;B were relatively lower in this group. Additional studies are required to determine how miR-16 and CIAPIN1 interact with the NF-&#x03BA;B signaling pathway.</p>
<p>In conclusion, the present study highlights the potential of targeting the miR-16/CIAPIN1 axis for treating MI/R-induced injury. However, additional <italic>in vivo</italic> studies are required to verify the present results. The association between miR-16 and other targets, such as serotonin transporter (SERT) (<xref rid="b36-mmr-20-04-3113" ref-type="bibr">36</xref>) and B lymphoma mouse Moloney leukemia virus insertion region (Bmi-1) (<xref rid="b37-mmr-20-04-3113" ref-type="bibr">37</xref>), in MI/R injury may also be worth studying to improve our understanding of the molecular mechanisms underlying the role of miR-16 in MI/R-induced injury.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>No funding was received.</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>HJZ and YNZ conceived the study. HJZ and ZYT conducted the experiments. HJZ wrote the manuscript. YNZ helped interpret the results and revised the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-mmr-20-04-3113"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name></person-group><article-title>Inhibition of miR-182-5p protects cardiomyocytes from hypoxia-induced apoptosis by targeting CIAPIN1</article-title><source>Biochem Cell Biol</source><volume>96</volume><fpage>646</fpage><lpage>654</lpage><year>2018</year><pub-id pub-id-type="doi">10.1139/bcb-2017-0224</pub-id><pub-id pub-id-type="pmid">29671338</pub-id></element-citation></ref>
<ref id="b2-mmr-20-04-3113"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forouzanfar</surname><given-names>MH</given-names></name><name><surname>Moran</surname><given-names>AE</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Roth</surname><given-names>G</given-names></name><name><surname>Mensah</surname><given-names>GA</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>CJ</given-names></name></person-group><article-title>Assessing the global burden of ischemic heart disease, part 2: Analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010</article-title><source>Glob Heart</source><volume>7</volume><fpage>331</fpage><lpage>342</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.gheart.2012.10.003</pub-id><pub-id pub-id-type="pmid">23505617</pub-id><pub-id pub-id-type="pmcid">3595103</pub-id></element-citation></ref>
<ref id="b3-mmr-20-04-3113"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillis</surname><given-names>LD</given-names></name><name><surname>Lange</surname><given-names>RA</given-names></name></person-group><article-title>Myocardial infarction and the open-artery hypothesis. N</article-title><source>Engl J Med</source><volume>355</volume><fpage>2475</fpage><lpage>2477</lpage><year>2006</year><pub-id pub-id-type="doi">10.1056/NEJMe068251</pub-id></element-citation></ref>
<ref id="b4-mmr-20-04-3113"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>YH</given-names></name><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>SF</given-names></name><name><surname>Tang</surname><given-names>TT</given-names></name><name><surname>Yan</surname><given-names>XX</given-names></name><name><surname>Lv</surname><given-names>BJ</given-names></name><name><surname>Nie</surname><given-names>SF</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration</article-title><source>J Am Coll Cardiol</source><volume>59</volume><fpage>420</fpage><lpage>429</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.jacc.2011.10.863</pub-id><pub-id pub-id-type="pmid">22261166</pub-id><pub-id pub-id-type="pmcid">3262985</pub-id></element-citation></ref>
<ref id="b5-mmr-20-04-3113"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name></person-group><article-title>MicroRNA-451 protects against cardiomyocyte anoxia/reoxygenation injury by inhibiting high mobility group box 1 expression</article-title><source>Mol Med Rep</source><volume>13</volume><fpage>5335</fpage><lpage>5341</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/mmr.2016.5192</pub-id><pub-id pub-id-type="pmid">27121079</pub-id></element-citation></ref>
<ref id="b6-mmr-20-04-3113"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Talukder</surname><given-names>MA</given-names></name></person-group><article-title>The role of oxidants and free radicals in reperfusion injury</article-title><source>Cardiovasc Res</source><volume>70</volume><fpage>181</fpage><lpage>190</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.cardiores.2006.02.025</pub-id><pub-id pub-id-type="pmid">16580655</pub-id></element-citation></ref>
<ref id="b7-mmr-20-04-3113"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosio</surname><given-names>G</given-names></name><name><surname>Tritto</surname><given-names>I</given-names></name></person-group><article-title>Myocardial reperfusion injury</article-title><source>J Thromb Thrombolysis</source><volume>4</volume><fpage>43</fpage><lpage>45</lpage><year>2007</year></element-citation></ref>
<ref id="b8-mmr-20-04-3113"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>IM</given-names></name><name><surname>Weintraub</surname><given-names>NL</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><article-title>miR322 mediates cardioprotection against ischemia/reperfusion injury via FBXW7/notch pathway</article-title><source>J Mol Cell Cardiol</source><volume>133</volume><fpage>67</fpage><lpage>74</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.yjmcc.2019.05.020</pub-id><pub-id pub-id-type="pmid">31150734</pub-id></element-citation></ref>
<ref id="b9-mmr-20-04-3113"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Kou</surname><given-names>B</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name></person-group><article-title>MicroRNA-30e protects the heart against ischemia and reperfusion injury through autophagy and the Notch1/Hes1/Akt signaling pathway</article-title><source>Int J Mol Med</source><volume>41</volume><fpage>3221</fpage><lpage>3230</lpage><year>2018</year><pub-id pub-id-type="pmid">29532851</pub-id><pub-id pub-id-type="pmcid">5881647</pub-id></element-citation></ref>
<ref id="b10-mmr-20-04-3113"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>RR</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>JY</given-names></name><name><surname>Kuang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>YS</given-names></name><name><surname>Ma</surname><given-names>QL</given-names></name><name><surname>Song</surname><given-names>CJ</given-names></name><name><surname>Truax</surname><given-names>AD</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><etal/></person-group><article-title>MicroRNA-141 regulates the expression level of ICAM-1 on endothelium to decrease myocardial ischemia-reperfusion injury</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>309</volume><fpage>H1303</fpage><lpage>H1313</lpage><year>2015</year><pub-id pub-id-type="doi">10.1152/ajpheart.00290.2015</pub-id><pub-id pub-id-type="pmid">26371161</pub-id></element-citation></ref>
<ref id="b11-mmr-20-04-3113"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Gui</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group><article-title>Differential expression of miR16 in glioblastoma and glioblastoma stem cells: Their correlation with proliferation, differentiation, metastasis and prognosis</article-title><source>Oncogene</source><volume>36</volume><fpage>5861</fpage><lpage>5873</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/onc.2017.182</pub-id><pub-id pub-id-type="pmid">28628119</pub-id><pub-id pub-id-type="pmcid">5658672</pub-id></element-citation></ref>
<ref id="b12-mmr-20-04-3113"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Dumitru</surname><given-names>CD</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Bichi</surname><given-names>R</given-names></name><name><surname>Zupo</surname><given-names>S</given-names></name><name><surname>Noch</surname><given-names>E</given-names></name><name><surname>Aldler</surname><given-names>H</given-names></name><name><surname>Rattan</surname><given-names>S</given-names></name><name><surname>Keating</surname><given-names>M</given-names></name><name><surname>Rai</surname><given-names>K</given-names></name><name><surname>Rassenti</surname><given-names>L</given-names></name><etal/></person-group><article-title>Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia</article-title><source>Proc Natl Acad Sci USA</source><volume>99</volume><fpage>15524</fpage><lpage>15529</lpage><year>2002</year><pub-id pub-id-type="doi">10.1073/pnas.242606799</pub-id><pub-id pub-id-type="pmid">12434020</pub-id></element-citation></ref>
<ref id="b13-mmr-20-04-3113"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Bu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group><article-title>Ischemic Postconditioning-mediated miRNA-21 protects against cardiac ischemia/reperfusion injury via PTEN/Akt pathway</article-title><source>PLoS One</source><volume>8</volume><fpage>e75872</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0075872</pub-id><pub-id pub-id-type="pmid">24098402</pub-id><pub-id pub-id-type="pmcid">3789724</pub-id></element-citation></ref>
<ref id="b14-mmr-20-04-3113"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Van Laake</surname><given-names>LW</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wendland</surname><given-names>MF</given-names></name><name><surname>Srivastava</surname><given-names>D</given-names></name></person-group><article-title>miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes</article-title><source>J Exp Med</source><volume>208</volume><fpage>549</fpage><lpage>560</lpage><year>2011</year><pub-id pub-id-type="doi">10.1084/jem.20101547</pub-id><pub-id pub-id-type="pmid">21383058</pub-id><pub-id pub-id-type="pmcid">3058576</pub-id></element-citation></ref>
<ref id="b15-mmr-20-04-3113"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Perez-Polo</surname><given-names>JR</given-names></name></person-group><article-title>Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury</article-title><source>Cardiovasc Res</source><volume>87</volume><fpage>535</fpage><lpage>544</lpage><year>2010</year><pub-id pub-id-type="doi">10.1093/cvr/cvq053</pub-id><pub-id pub-id-type="pmid">20164119</pub-id></element-citation></ref>
<ref id="b16-mmr-20-04-3113"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b17-mmr-20-04-3113"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>MicroRNA-486 alleviates Hypoxia-induced damage in H9c2 cells by targeting NDRG2 to inactivate JNK/C-Jun and NF-&#x03BA;B signaling pathways</article-title><source>Cell Physiol Biochem</source><volume>48</volume><fpage>2483</fpage><lpage>2492</lpage><year>2018</year><pub-id pub-id-type="doi">10.1159/000493874</pub-id><pub-id pub-id-type="pmid">30121658</pub-id></element-citation></ref>
<ref id="b18-mmr-20-04-3113"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Lan</surname><given-names>YF</given-names></name><name><surname>Li</surname><given-names>HF</given-names></name><name><surname>Cheng</surname><given-names>CF</given-names></name><name><surname>Lai</surname><given-names>PF</given-names></name><name><surname>Li</surname><given-names>WH</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name></person-group><article-title>Urinary miR-16 transactivated by C/EBP&#x03B2; reduces kidney function after ischemia/reperfusion-induced injury</article-title><source>Sci Rep</source><volume>6</volume><fpage>27945</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep27945</pub-id><pub-id pub-id-type="pmid">27297958</pub-id><pub-id pub-id-type="pmcid">4906401</pub-id></element-citation></ref>
<ref id="b19-mmr-20-04-3113"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Tong</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma</article-title><source>J Cell Biochem</source><volume>111</volume><fpage>727</fpage><lpage>734</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/jcb.22762</pub-id><pub-id pub-id-type="pmid">20626035</pub-id></element-citation></ref>
<ref id="b20-mmr-20-04-3113"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>miR-16 induced the suppression of cell apoptosis while promote proliferation in esophageal squamous cell carcinoma</article-title><source>Cell Physiol Biochem</source><volume>33</volume><fpage>1340</fpage><lpage>1348</lpage><year>2014</year><pub-id pub-id-type="doi">10.1159/000358701</pub-id><pub-id pub-id-type="pmid">24852767</pub-id></element-citation></ref>
<ref id="b21-mmr-20-04-3113"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>JH</given-names></name><name><surname>Lung</surname><given-names>RW</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Pang</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma</article-title><source>Mol Cancer</source><volume>14</volume><fpage>52</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/s12943-015-0323-3</pub-id><pub-id pub-id-type="pmid">25743273</pub-id><pub-id pub-id-type="pmcid">4342823</pub-id></element-citation></ref>
<ref id="b22-mmr-20-04-3113"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>CH</given-names></name><name><surname>Fang</surname><given-names>XB</given-names></name><name><surname>Li</surname><given-names>WF</given-names></name><name><surname>Shi</surname><given-names>QY</given-names></name><name><surname>Wu</surname><given-names>LP</given-names></name><name><surname>Chen</surname><given-names>XY</given-names></name><name><surname>Huang</surname><given-names>ZX</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><name><surname>Liao</surname><given-names>ZS</given-names></name></person-group><article-title>Influence of recombinant lentiviral vector encoding miR-15a/16-1 in biological features of human nasopharyngeal carcinoma CNE-2Z cells</article-title><source>Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</source><volume>48</volume><fpage>405</fpage><lpage>411</lpage><year>2013</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">24016566</pub-id></element-citation></ref>
<ref id="b23-mmr-20-04-3113"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibayama</surname><given-names>H</given-names></name><name><surname>Takai</surname><given-names>E</given-names></name><name><surname>Matsumura</surname><given-names>I</given-names></name><name><surname>Kouno</surname><given-names>M</given-names></name><name><surname>Morii</surname><given-names>E</given-names></name><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Kanakura</surname><given-names>Y</given-names></name></person-group><article-title>Identification of a cytokine-induced antiapoptotic molecule anamorsin essential for definitive hematopoiesis</article-title><source>J Exp Med</source><volume>199</volume><fpage>581</fpage><lpage>592</lpage><year>2004</year><pub-id pub-id-type="doi">10.1084/jem.20031858</pub-id><pub-id pub-id-type="pmid">14970183</pub-id><pub-id pub-id-type="pmcid">2211823</pub-id></element-citation></ref>
<ref id="b24-mmr-20-04-3113"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Pang</surname><given-names>T</given-names></name></person-group><article-title>Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-&#x03BA;B and ERK5 signaling pathway</article-title><source>Biochem Pharmacol</source><volume>99</volume><fpage>132</fpage><lpage>145</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.bcp.2015.12.002</pub-id><pub-id pub-id-type="pmid">26679828</pub-id></element-citation></ref>
<ref id="b25-mmr-20-04-3113"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Bi</surname><given-names>XX</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>G</given-names></name></person-group><article-title>The study on expression of CIAPIN1 interfering hepatocellular carcinoma cell proliferation and its mechanisms</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>21</volume><fpage>3054</fpage><lpage>3060</lpage><year>2017</year><pub-id pub-id-type="pmid">28742201</pub-id></element-citation></ref>
<ref id="b26-mmr-20-04-3113"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ray</surname><given-names>PS</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Shin-Sim</surname><given-names>M</given-names></name><name><surname>Bukoye</surname><given-names>BA</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>AV</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-&#x03BA;B signaling</article-title><source>J Clin Invest</source><volume>121</volume><fpage>212</fpage><lpage>225</lpage><year>2011</year><pub-id pub-id-type="doi">10.1172/JCI43144</pub-id><pub-id pub-id-type="pmid">21123948</pub-id></element-citation></ref>
<ref id="b27-mmr-20-04-3113"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Schiavon</surname><given-names>G</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><name><surname>Gaeta</surname><given-names>L</given-names></name><name><surname>Pantano</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Ortega</surname><given-names>C</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Galluzzo</surname><given-names>S</given-names></name><name><surname>Armento</surname><given-names>G</given-names></name><etal/></person-group><article-title>Receptor activator of NF-&#x03BA;B (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients</article-title><source>PLoS One</source><volume>6</volume><fpage>e19234</fpage><year>2011</year><pub-id pub-id-type="doi">10.1371/journal.pone.0019234</pub-id><pub-id pub-id-type="pmid">21559440</pub-id><pub-id pub-id-type="pmcid">3084800</pub-id></element-citation></ref>
<ref id="b28-mmr-20-04-3113"><label>28</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><chapter-title>The effect of overexpressed CIAPIN1on H9c2 myocytes H/R damage</chapter-title><publisher-name>Tianjin Medical University</publisher-name><year>2016</year></element-citation></ref>
<ref id="b29-mmr-20-04-3113"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>HR</given-names></name><name><surname>Jin</surname><given-names>SZ</given-names></name><name><surname>Cai</surname><given-names>XF</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Nan</surname><given-names>JX</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name></person-group><article-title>Cryptopleurine targets NF-&#x03BA;B pathway, leading to inhibition of gene products associated with cell survival, proliferation, invasion, and angiogenesis</article-title><source>PLoS One</source><volume>7</volume><fpage>e40355</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0040355</pub-id><pub-id pub-id-type="pmid">22768286</pub-id><pub-id pub-id-type="pmcid">3386984</pub-id></element-citation></ref>
<ref id="b30-mmr-20-04-3113"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Fei</surname><given-names>J</given-names></name><name><surname>Bo</surname><given-names>Q</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Mycophenolate mofetil attenuates myocardial ischemia-reperfusion injury via regulation of the TLR4/NF-&#x03BA;B signaling pathway</article-title><source>Pharmazie</source><volume>69</volume><fpage>850</fpage><lpage>855</lpage><year>2014</year><pub-id pub-id-type="pmid">25985583</pub-id></element-citation></ref>
<ref id="b31-mmr-20-04-3113"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Mu</surname><given-names>XD</given-names></name><name><surname>Gao</surname><given-names>ZY</given-names></name></person-group><article-title>Protective effect of down-regulated microRNA-27a mediating high thoracic epidural block on myocardial ischemia-reperfusion injury in mice through regulating ABCA1 and NF-&#x03BA;B signaling pathway</article-title><source>Biomed Pharmacother</source><volume>112</volume><fpage>108606</fpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.biopha.2019.108606</pub-id><pub-id pub-id-type="pmid">30802823</pub-id></element-citation></ref>
<ref id="b32-mmr-20-04-3113"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Dou</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name></person-group><article-title>The protective effect of Luteolin on myocardial ischemia/reperfusion (I/R) injury through TLR4/NF-&#x03BA;B/NLRP3 inflammasome pathway</article-title><source>Biomed Pharmacother</source><volume>91</volume><fpage>1042</fpage><lpage>1052</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.biopha.2017.05.033</pub-id><pub-id pub-id-type="pmid">28525945</pub-id></element-citation></ref>
<ref id="b33-mmr-20-04-3113"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Hu J Zheng</surname><given-names>R</given-names></name><etal/></person-group><article-title>MicroRNA-16 is putatively involved in the NF-&#x03BA;B pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting</article-title><source>Sci Rep</source><volume>6</volume><fpage>30824</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep30824</pub-id><pub-id pub-id-type="pmid">27476546</pub-id><pub-id pub-id-type="pmcid">4967855</pub-id></element-citation></ref>
<ref id="b34-mmr-20-04-3113"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Tan</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Puerarin inhibits proliferation and induces apoptosis by up-regulation of miR-16 in bladder cancer cell line T24</article-title><source>Oncol Res</source><volume>26</volume><fpage>1227</fpage><lpage>1234</lpage><year>2018</year><pub-id pub-id-type="doi">10.3727/096504018X15178736525106</pub-id><pub-id pub-id-type="pmid">29422113</pub-id></element-citation></ref>
<ref id="b35-mmr-20-04-3113"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>TQ</given-names></name><name><surname>Luo</surname><given-names>XJ</given-names></name><name><surname>Wu</surname><given-names>TF</given-names></name><name><surname>Ding</surname><given-names>DD</given-names></name><name><surname>Zhao</surname><given-names>ZH</given-names></name><name><surname>Chen</surname><given-names>GL</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>YX</given-names></name><name><surname>Guo</surname><given-names>LC</given-names></name><etal/></person-group><article-title>miR-16 inhibits glioma cell growth and invasion through the suppression of BCL2 and NF-&#x03BA;B1/MMP-9 signaling pathway</article-title><source>Cancer Sci</source><volume>105</volume><fpage>265</fpage><lpage>271</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/cas.12351</pub-id><pub-id pub-id-type="pmid">24418124</pub-id><pub-id pub-id-type="pmcid">4317940</pub-id></element-citation></ref>
<ref id="b36-mmr-20-04-3113"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudry</surname><given-names>A</given-names></name><name><surname>Mouillet-Richard</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>B</given-names></name><name><surname>Launay</surname><given-names>JM</given-names></name><name><surname>Kellermann</surname><given-names>O</given-names></name></person-group><article-title>miR-16 targets the serotonin transporter: A new Facet for adaptive responses to antidepressants</article-title><source>Science</source><volume>329</volume><fpage>1537</fpage><lpage>1541</lpage><year>2010</year><pub-id pub-id-type="doi">10.1126/science.1193692</pub-id><pub-id pub-id-type="pmid">20847275</pub-id></element-citation></ref>
<ref id="b37-mmr-20-04-3113"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>R</given-names></name><name><surname>Nicoloso</surname><given-names>M</given-names></name><name><surname>Arvizo</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Cortez</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Mukherjee</surname><given-names>P</given-names></name></person-group><article-title>miR-15a and miR-16 control Bmi-1 expression in ovarian cancer</article-title><source>Cancer Res</source><volume>69</volume><fpage>9090</fpage><lpage>9095</lpage><year>2009</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2552</pub-id><pub-id pub-id-type="pmid">19903841</pub-id><pub-id pub-id-type="pmcid">2859686</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-20-04-3113" position="float">
<label>Figure 1.</label>
<caption><p>mRNA expression levels of miR-16 in H9c2 cells following H/R. (A) mRNA expression levels of miR-16 were significantly upregulated in H9c2 cells following H/R compared to the sham treatment. &#x002A;&#x002A;P&#x003C;0.01. (B) mRNA expression levels of miR-16 were increased or decreased in H9c2 cells following transfection with miR-16 mimics or miR-16 inhibitor, respectively. &#x002A;&#x002A;P&#x003C;0.01 vs. miR-16 mimics NC, <sup>##</sup>P&#x003C;0.01 vs. miR-16 inhibitor NC. (C) mRNA expression levels of miR-16 were increased or decreased by miR-16 mimics or the miR-16 inhibitor, respectively, in the H/R model. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. miR-16 mimics NC, <sup>&#x0024;&#x0024;</sup>P&#x003C;0.01 vs. miR-16 inhibitor NC. miR, microRNA; NC, negative control; H/R, hypoxia/reoxygenation.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g00.tif"/>
</fig>
<fig id="f2-mmr-20-04-3113" position="float">
<label>Figure 2.</label>
<caption><p>Effect of miR-16 expression on the viability of H9c2 cells following H/R, determined using a cell counting kit-8 assay. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. miR, microRNA; NC, negative control; H/R, hypoxia/reoxygenation.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g01.tif"/>
</fig>
<fig id="f3-mmr-20-04-3113" position="float">
<label>Figure 3.</label>
<caption><p>miR-16 regulates the apoptosis of H9c2 cells following H/R. Effect of miR-16 expression on apoptosis of H9c2 cells following H/R was determined using flow cytometry. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. miR, microRNA; NC, negative control; H/R, hypoxia/reoxygenation.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g02.tif"/>
</fig>
<fig id="f4-mmr-20-04-3113" position="float">
<label>Figure 4.</label>
<caption><p>Effect of miR-16 on the expression of apoptosis-associated proteins in H9c2 cells following H/R. (A) Protein expression levels of Bcl-2, Bax and cleaved-caspase-3 were determined by western blotting. Relative expression levels of (B) Bcl-2, (C) Bax and (D) cleaved caspase-3. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. miR, microRNA; NC, negative control; H/R, hypoxia/reoxygenation.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g03.tif"/>
</fig>
<fig id="f5-mmr-20-04-3113" position="float">
<label>Figure 5.</label>
<caption><p>miR-16 directly binds to the 3&#x2032;-untranslated region of CIAPIN1. (A) Predicted binding site of miR-16 with CIAPIN1 and the mutated binding site used in the present study. (B) Luciferase activity in cells transfected with miR-16 mimics &#x002B; WT or miR-16 mimics &#x002B; Mut compared with cells transfected with miR-16 mimics NC &#x002B; WT and miR-16 mimics NC &#x002B; Mut. &#x002A;&#x002A;P&#x003C;0.01 vs. H/R&#x002B;miR-16 mimic NC. CIAPIN1, cytokine-induced apoptosis inhibitor 1; MUT, mutated; WT, wildtype; miR, microRNA; NC, negative control; H/R, hypoxia/reoxygenation.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g04.tif"/>
</fig>
<fig id="f6-mmr-20-04-3113" position="float">
<label>Figure 6.</label>
<caption><p>Transfection with miR-16 mimics decreases the expression levels of CIAPIN1 following H/R. (A) mRNA expression levels of CIAPIN1 in H9c2 cells were detected by qPCR. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. (B) Protein expression levels of CIAPIN1 in H9c2 cells were determined by western blotting. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>#</sup>P&#x003C;0.05, <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. CIAPIN1, cytokine induced apoptosis inhibitor 1; miR, microRNA; NC, negative control; H/R, hypoxia/reoxygenation.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g05.tif"/>
</fig>
<fig id="f7-mmr-20-04-3113" position="float">
<label>Figure 7.</label>
<caption><p>Effect of CIAPIN1 overexpression on the expression of apoptosis-associated proteins in H9c2 cells following H/R. (A) mRNA expression levels of CIAPIN1 in H9c2 cells transfected with pcDNA3.1-CIAPIN1 compared with cells transfected with the empty vector. &#x002A;&#x002A;P&#x003C;0.01. (B) Protein expression levels of CIAPIN1 in H9c2 cells was detected by western blotting. (C) Relative protein expression levels of CIAPIN1 in H9c2 cells transfected with pcDNA3.1-CIAPIN1 compared with cells transfected with the empty vector. &#x002A;&#x002A;P&#x003C;0.01. (D) Expression levels of Bcl-2 and Bax were determined by western blotting. (E) Relative expression levels of Bcl-2 and Bax. &#x002A;P&#x003C;0.05. CIAPIN1, cytokine induced apoptosis inhibitor 1; H/R, hypoxia/reoxygenation; OE, overexpression; vector, empty vector.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g06.tif"/>
</fig>
<fig id="f8-mmr-20-04-3113" position="float">
<label>Figure 8.</label>
<caption><p>Effect of miR-16 on the expression of NF-&#x03BA;B, p-NF-&#x03BA;B, I&#x03BA;B&#x03B1; and p-I&#x03BA;B&#x03B1;. (A) Protein expression levels of NF-&#x03BA;B, p-NF-&#x03BA;B, I&#x03BA;B&#x03B1; and p-I&#x03BA;B&#x03B1; were determined by western blot. (B) Relative protein expression levels of p-NF-&#x03BA;B in cells following H/R and/or transfection of the miR-mimics or inhibitors. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. (C) Relative protein expression levels of p-I&#x03BA;B&#x03B1; in cells following H/R and/or transfection of the miR-mimics or inhibitors. &#x002A;&#x002A;P&#x003C;0.01 vs. sham; <sup>##</sup>P&#x003C;0.01 vs. H/R&#x002B;NC. miR, microRNA; H/R, hypoxia/reoxygenation; p-, phospho; NC, negative control; NF-&#x03BA;B, nuclear factor-&#x03BA;B; I&#x03BA;B&#x03B1;, NF-&#x03BA;B inhibitor &#x03B1;.</p></caption>
<graphic xlink:href="MMR-20-04-3113-g07.tif"/>
</fig>
<table-wrap id="tI-mmr-20-04-3113" position="float">
<label>Table I.</label>
<caption><p>Primer sequences.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom" colspan="2">A, mRNA primer sequences</th>
</tr>
<tr>
<th align="left" valign="bottom">Primer</th>
<th align="center" valign="bottom">Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">CIAPIN1 F</td>
<td align="left" valign="top">5&#x2032;-GCTTGTGGCAGTGTTCTGTG-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="top">CIAPIN1 R</td>
<td align="left" valign="top">5&#x2032;-CACAGAACACTGCCACAAGC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="top">GAPDH F</td>
<td align="left" valign="top">5&#x2032;-GCCAGCCTCGTCTCATAGAC-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="top">GAPDH R</td>
<td align="left" valign="top">5&#x2032;-AGTGATGGCATGGACTGTGG-3&#x2032;</td>
</tr>
<tr>
<td align="center" valign="top" colspan="2"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"><bold>B, miRNA primer sequences</bold></td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"><hr/></td>
</tr>
<tr>
<td align="left" valign="top"><bold>Primer</bold></td>
<td align="center" valign="top"><bold>Sequence</bold></td>
</tr>
<tr>
<td align="center" valign="top" colspan="2"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">miR-16 F</td>
<td align="left" valign="top">5&#x2032;-GCGTAGCAGCACGTAAAT-3&#x2032;</td>
</tr>
<tr>
<td align="left" valign="top">miR-16 R</td>
<td align="left" valign="top">Uni-miR qPCR Primer</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-mmr-20-04-3113"><p>miR, microRNA; CIAPIN1, cytokine-induced apoptosis inhibitor 1; F, forward; R, reverse; qPCR, quantitative PCR.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>